NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

KMTS

Kestra Medical Technologies Ltd

Last Close
May 22 04:00PM ET
22.30
Dollar change
-0.79
Percentage change
-3.42
%
Index- P/E- EPS (ttm)-1.90 Insider Own69.51% Shs Outstand51.35M Perf Week-6.11%
Market Cap1.15B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float15.66M Perf Month-8.38%
Income-95.07M PEG- EPS next Q-0.53 Inst Own26.27% Short Float6.07% Perf Quarter-
Sales52.64M P/S21.75 EPS this Y- Inst Trans-59.32% Short Ratio3.54 Perf Half Y-
Book/sh-5.34 P/B- EPS next Y- ROA- Short Interest0.95M Perf Year-
Cash/sh1.06 P/C21.07 EPS next 5Y- ROE- 52W Range20.00 - 26.15 Perf YTD2.11%
Dividend Est.- P/FCF- EPS past 5Y- ROI-179.15% 52W High-14.72% Beta-
Dividend TTM- Quick Ratio1.65 Sales past 5Y264.53% Gross Margin37.73% 52W Low11.50% ATR (14)1.57
Dividend Ex-Date- Current Ratio1.81 EPS Y/Y TTM- Oper. Margin-149.17% RSI (14)44.39 Volatility4.32% 3.69%
Employees- Debt/Eq7.22 Sales Y/Y TTM- Profit Margin-180.62% Recom1.33 Target Price27.50
Option/ShortNo / Yes LT Debt/Eq7.22 EPS Q/Q-2.24% Payout- Rel Volume0.47 Prev Close23.09
Sales Surprise0.12% EPS Surprise-107.19% Sales Q/Q82.31% EarningsApr 14 AMC Avg Volume268.60K Price22.30
SMA20-4.78% SMA50-5.84% SMA200-4.95% Trades Volume127,565 Change-3.42%
Date Action Analyst Rating Change Price Target Change
Mar-31-25Initiated Wolfe Research Outperform $29
Mar-31-25Initiated Wells Fargo Overweight $28
Mar-31-25Initiated Stifel Buy $28
Mar-31-25Initiated Piper Sandler Overweight $27
Mar-31-25Initiated Goldman Neutral $24
Mar-31-25Initiated BofA Securities Buy $30
Kestra Medical Technologies Ltd. operates as a commercial-stage, wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company was founded by Brian Webster and Phillip D. Foshee in 2014 and is headquartered in Kirkland, WA.